02877.HK
China Shineway Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 8.13
−2.11%Year over year
Reported trailing growth
- Revenue
- -20.8%
- EBITDA
- -1.7%
- EBIT
- -0.0%
- EPS
- -3.7%
- Free cash flow
- +21.9%
- Operating cash flow
- +21.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.4%
- EBITDA
- -12.5%
- EBIT
- -1.5%
- Net income
- +9.5%
- EPS
- +9.5%
- Free cash flow
- -0.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026